natgillin/translations-raw huggingface dataset:
Patienter co-inficeret med hepatitis B og/eller hepatitis C Der foreligger kun begrænsede oplysninger om brug af REZOLSTA hos patienter co-inficeret med hepatitis B og/eller C. Blandt 1.968 behandlingserfarne patienter, der fik darunavir coadministreret med ritonavir, 600/100 mg to gange dagligt, havde 236 patienter også hepatitis B eller C. Disse patienter var mere tilbøjelige til at have forhøjede hepatiske aminotransferaser ved baseline og efter behandlingsstart end patienter uden kronisk viral hepatitis (se pkt.
Among 1,968 treatment-experienced patients receiving darunavir co-administered with ritonavir 600/100 mg twice daily, 236 patients were co-infected with hepatitis B or C. Co-infected patients were more likely to have baseline and treatment emergent hepatic transaminase elevations than those without chronic viral hepatitis (see section 4.4).
Co-administration af REZOLSTA og efavirenz frarådes.
Co-administration of REZOLSTA and efavirenz is not recommended.
- colchicin (til behandling af urinsur gigt eller familiær middelhavsfeber).
Colchicine (if you have kidney/liver problems) to treat gout or familial Mediterranean fever The combination product lopinavir/ritonavir anti-HIV medicine
Hvis du har taget for mange REZOLSTA Kontakt straks din læge, apotekspersonalet eller sundhedspersonalet.
If you take more REZOLSTA than you should Contact your doctor, pharmacist or nurse immediately.
Med CD4+-celletal (x 10
With Baseline CD4+ cell count (x 10
Klinisk monitorering anbefales ved co-administration af REZOLSTA og disse betablokkere, og lavere dosis af disse betablokkere bør overvejes.
Clinical monitoring is recommended when co-administering REZOLSTA with beta-blockers and a lower dose of the beta-blocker should be considered.
4.5) - sildenafil til behandling af pulmonal arteriel hypertension, avanafil - simvastatin, lovastatin og lomitapid (se pkt.
see section 4.5) - sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil - simvastatin, lovastatin and lomitapide (see section 4.5) - dabigatran, ticagrelor.
Interaktionsprofilen for darunavir afhænger af, om ritonavir eller cobicistat benyttes som farmakokinetisk forstærker.
The interaction profile of darunavir depends on whether ritonavir or cobicistat is used as pharmacokinetic enhancer, therefore there may be different recommendations for the use of darunavir with concomitant medicine.
Ved co-administration er terapeutisk lægemiddelmonitorering af det immunsupprimerende middel nødvendig.
Therapeutic drug monitoring of the immunosuppressive agent must be done when co-administration occurs.
Kombinationen af rifampicin og REZOLSTA er kontraindiceret (se pkt.
The combination of rifampicin and REZOLSTA is contraindicated (see section 4.3).
4.2 og 4.4).
6/l (see sections 4.2 and 4.4).
(hæmning af CYP3A)
(inhibition of CYP3A)
almindelig ikke almindelig pruritus
Common pruritus
REZOLSTA forventes at øge plasmakoncentrationen af nevirapin.
REZOLSTA is expected to increase nevirapine plasma concentrations.
REZOLSTAs sikkerhed og virkning hos pædiatriske patienter i alderen 3 til 17 år er ikke klarlagt (se pkt.
The safety and efficacy of REZOLSTA in paediatric patients aged 3 to 17 years has not been established (see sections 4.4 and 5.3).
Det anbefales at bruge andre trombocythæmmende midler, som ikke påvirkes af CYPhæmning eller -induktion (f.eks. prasugrel se pkt.
Use of other antiplatelets not affected by CYP inhibition or induction (e.g. prasugrel) is recommended (see section 4.3).
Nedsat nyrefunktion REZOLSTA er ikke undersøgt hos patienter med nedsat nyrefunktion.
Renal impairment REZOLSTA has not been investigated in patients with renal impairment.
lopinavir/ ritonavir 800/200 mg dagligt N=346
lopinavir/ ritonavir 800/200 mg per day N = 346
REZOLSTA og didanosin kan anvendes uden dosisjustering.
REZOLSTA and didanosine can be used without dose adjustments.
Baseret på teoretiske overvejelser kan REZOLSTA muligvis øge plasmakoncentrationen af disse analgetika.
Based on theoretical considerations REZOLSTA may increase plasma concentrations of these analgesics.
Co-administration af REZOLSTA og dapoxetin er kontraindiceret.
Co-administration of REZOLSTA with dapoxetine is contraindicated.
Din læge vil muligvis foretage yderligere test. - kortikosteroider, herunder betamethason, budesonid, fluticason, mometason, prednison og triamcinolon.
- Corticosteroids including betamethasone, budesonide, fluticasone, mometasone, prednisone,
Co-administration af REZOLSTA og disse antiepileptika er kontraindicerede (se pkt.
Co-administration of REZOLSTA and these anticonvulsants is contraindicated (see section 4.3).
Behandling med REZOLSTA bør ikke initieres hos patienter med kreatininclearance under 70 ml/min, hvis dosisjustering på basis af kreatininclearance er nødvendigt for et samtidigt administreret lægemiddel (f.eks. emtricitabin, lamivudin, tenofovirdisoproxil (som fumarat, fosfat eller succinat) eller adefovirdipivoxil) (se pkt.
REZOLSTA should not be initiated in patients with creatinine clearance less than 70 mL/min when co-administered with one or more agent requiring dose adjustment based on creatinine clearance (e.g. emtricitabine, lamivudine, tenofovir disoproxil (as fumarate, phosphate or succinate) or adefovir dipivoxil) (see sections 4.2, 4.8 and 5.2).
Metabolisme og ernæring almindelig anoreksi, hyperkolesterolæmi, hypertriglyceridæmi ikke almindelig diabetes mellitus, dyslipidæmi, hyperglykæmi, hyperlipidæmi
Metabolism and nutrition disorders Common anorexia, hypercholesterolaemia, hypertriglyceridaemia
Triazolam eller oral (taget gennem munden) midazolam som sovemiddel og/eller til at afhjælpe angst
Triazolam or oral (taken by mouth) midazolam to help you sleep and/or relieve anxiety Sildenafil to treat a heart and lung disorder called pulmonary arterial hypertension.
Baseret på teoretiske overvejelser forventes REZOLSTA at øge plasmakoncentrationen af antimykotika, og plasmakoncentrationen af darunavir og/eller cobicistat kan øges af de pågældende antimykotika.
Based on theoretical considerations REZOLSTA is expected to increase these antifungal plasma concentrations, and darunavir and/or cobicistat plasma concentrations may be increased by the antifungals.
Baseret på teoretiske overvejelser forventes REZOLSTA at øge koncentrationen af clonazepam.
Based on theoretical considerations REZOLSTA is expected to increase concentrations of clonazepam.
Genotypebestemmelse skal være vejledende for brugen af REZOLSTA (se pkt.
Genotypic testing should guide the use of REZOLSTA (see sections 4.2, 4.4 and 5.1).
Baseret på teoretiske overvejelser forventes REZOLSTA at øge plasmakoncentrationen af disse sedativa/hypnotika.
Based on theoretical considerations REZOLSTA is expected to increase these sedative/hypnotic plasma concentrations.
Co-administration af REZOLSTA og nevirapin frarådes.
Co-administration of REZOLSTA and nevirapine is not recommended.
Behandlingsnaive darunavir/cobicistat 800/150 mg en gang dagligt + emtricitabine/tenofovirdisoproxilfumarat N = 363
Treatment-naïve darunavir/cobicistat 800/150 mg once daily + emtricitabine/tenofovir disoproxil fumarate N = 363
Baseret på teoretiske overvejelser forventes nevirapin at nedsætte plasmakoncentrationen af darunavir og/eller cobicistat (CYP3A-induktion).
Based on theoretical considerations nevirapine is expected to decrease darunavir and/or cobicistat plasma concentrations, (CYP3A induction).
(CYP3A-, CYP2D6- og/eller P-gp-hæmning)
(CYP3A, CYP2D6 and/or P-gp inhibition)
Der blev ikke observeret krydsresistens med andre hiv-PI'er i de virologiske svigt fra studiet GS-US216-130.
In the virologic failures of the GS-US-216-130 trial no cross-resistance with other HIV PIs was observed.
REZOLSTA 800 mg/150 mg filmovertrukne tabletter darunavir/cobicistat
REZOLSTA 800 mg/150 mg film-coated tablets darunavir/cobicistat
Du skal straks informere din læge, så du kan få den nødvendige behandling, hvis du bemærker symptomer på infektion eller andre symptomer, såsom muskelsvaghed, svaghed begyndende i hænder og fødder, og som bevæger sig op igennem kroppen, hjertebanken, rysten eller hyperaktivitet.
If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately so you can be given the necessary treatment.
Samtidig brug af REZOLSTA og lovastatin eller simvastatin er kontraindiceret (se pkt.
Concomitant use of REZOLSTA with lovastatin and simvastatin is contraindicated (see section 4.3).
I REZOLSTA-armen i fase III-studiet TMC114FD2HTX3001 var den gennemsnitlige ændring i eGFRCG fra baseline -11,1 ml/min.
In the REZOLSTA arm of Phase III trial TMC114FD2HTX3001, mean eGFRCG change from baseline was -11.1 mL/min at week 48 and mean eGFRcystatin C change from baseline was +2.9 mL/min/1.73 m² at week 48.
REZOLSTA og tenofovirdisoproxil kan anvendes uden dosisjustering.
REZOLSTA and tenofovir disoproxil can be used without dose adjustments.
- buspiron, clorazepat, diazepam, estazolam, flurazepam, zolpidem og midazolam brugt som injektion (medicin til behandling af søvnforstyrrelser og/eller angst).
- Bosentan (to treat high blood pressure in the pulmonary circulation) - Buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem, midazolam when used as injection (medicines to treat trouble with sleeping and/or anxiety) - Metformin (to treat type 2 diabetes) - Fentanyl, oxycodone, tramadol (to treat pain).
REZOLSTA bør ikke anvendes til pædiatriske patienter under 3 år (se pkt.
REZOLSTA should not be used in paediatric patients below 3 years of age (see sections 4.2 and 5.3).
Virkning af darunavir 800 mg en gang dagligt co-administreret med 100 mg ritonavir en gang dagligt hos ART-erfarne patienter
Efficacy of darunavir 800 mg once daily co-administered with 100 mg ritonavir once daily in ART-experienced patients
Der skal udvises forsigtighed ved kombination af disse antineoplastika og REZOLSTA.
Caution should be exercised when combining one of these anti-neoplastic agents with REZOLSTA.
Mave-tarm-kanalen meget almindelig diarré, kvalme almindelig opkastning, abdominalsmerter, abdominal distention, dyspepsi, flatulens ikke almindelig akut pankreatitis, forhøjede pankreasenzymer
Common vomiting, abdominal pain, abdominal distension, dyspepsia, flatulence
Behandling med REZOLSTA bør ikke initieres hos patienter med kreatininclearance under 70 ml/min, hvis dosisjustering på basis af kreatininclearance for et samtidigt administreret lægemiddel (f.eks. emtricitabin, lamivudin, tenofovirdisoproxilfumarat (som furamat, fosfat eller succinat) eller adefovirdipivoxil) er nødvendig (se pkt.
REZOLSTA should not be initiated in patients with creatinine clearance less than 70 mL/min, if any co-administered medicinal product (e.g. emtricitabine, lamivudine, tenofovir disoproxil (as fumarate, phosphate or succinate), or adefovir dipivoxil) requires dose adjustment based on creatinine clearance (see sections 4.4, 4.8 and 5.2).
Hos kvinder, der fik REZOLSTA i andet trimester af graviditeten, var de gennemsnitlige intraindividuelle værdier for Cmax, AUC24t og Cmin for total-darunavir hhv. 49 %, 56 % og 92 % lavere i forhold til post partum.
In women receiving REZOLSTA during the second trimester of pregnancy, mean intra-individual values for total darunavir Cmax, AUC24h and Cmin were 49%, 56% and 92% lower, respectively, as compared with postpartum; during the third trimester of pregnancy, total darunavir Cmax, AUC24h and Cmin values were 37%, 50% and 89% lower, respectively, as compared with postpartum.
Virkningen af darunavir 800 mg en gang dagligt co-administreret med 150 mg cobicistat en gang dagligt hos ART-naive og ART-erfarne patienter
Efficacy of darunavir 800 mg once daily co-administered with 150 mg cobicistat once daily in ART-naïve and ART-experienced patients
Samtidig administration af REZOLSTA og alfuzosin er kontraindiceret (se pkt.
Co-administration of REZOLSTA with alfuzosin is contraindicated (see section 4.3).
darunavir/ritonavir 600/100 mg to gange dagligt + OBR N=296
darunvir/ritonavir 600/100 mg twice daily + OBR N = 296
Virkning af darunavir 800 mg en gang dagligt co-administreret med 100 mg ritonavir en gang dagligt hos ART-naive patienter
Efficacy of darunavir 800 mg once daily co-administered with 100 mg ritonavir once daily in ART-naïve patients
Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 personer) - symptomer på infektion eller på autoimmune lidelser (immunrekonstitutionsinflammatorisk syndrom (IRIS)) - osteonekrose (hvor knoglevævet dør på grund af manglende blodforsyning til knoglen) - udvikling af bryster hos mænd (gynækomasti) - unormale resultater af blodprøver som for eksempel undersøgelser af bugspytkirtel, højt sukkerniveau, unormale niveauer af "lipider" (fedtstoffer); din læge vil forklare dig om dette - allergiske reaktioner som for eksempel nældefeber (urticaria), svær hævelse af huden og andre væv (oftest læberne eller øjnene) - alvorligt udslæt med blærer og og afskallende hud, især omkring munden, næsen, øjnene og kønsorganerne.
Uncommon side effects (may affect up to 1 in 100 people) - symptoms of infection or of autoimmune disorders (immune reconstitution inflammatory syndrome) - osteonecrosis (death of bone tissue caused by loss of blood supply to the bone) - enlargement of breasts - abnormal blood test results such as some tests for your pancreas, high level of sugar, abnormal levels of ‘lipids' (fats).
ANTIRETROVIRALE MIDLER MOD HIV Integrasehæmmere
HIV ANTIRETROVIRALS Integrase strand transfer inhibitors Dolutegravir
Behandlingserfarne darunavir/ritonavir 600/100 mg to gange dagligt N=296
Treatment-experienced darunavir/ritonavir 600/100 mg twice daily N = 296
Co-administration af REZOLSTA og etravirin frarådes.
Co-administration of REZOLSTA and etravirine is not recommended.
REZOLSTA bør af sikkerhedsmæssige grunde ikke anvendes til pædiatriske patienter under 3 år (se pkt.
REZOLSTA should not be used in paediatric patients below 3 years of age because of safety concerns (see sections 4.4 and 5.3).
Baseret på teoretiske overvejelser kan REZOLSTA muligvis øge plasmakoncentrationen af methadon.
Based on theoretical considerations REZOLSTA may increase methadone plasma concentrations.
Hvis du kommer i tanke om den glemte dosis inden for 12 timer, skal du straks tage den. Skal altid tages sammen med mad.
If you notice within 12 hours, you must take the tablet immediately.
urticaria sjælden eosinofili og systemiske symptomer* som reaktion over for lægemidlet ikke kendt toksisk epidermal nekrolyse*, akut generaliseret eksantematøs pustulose*
Not known toxic epidermal necrolysis*, acute generalised exanthematous pustulosis*
Samtidig administration af avanafil og REZOLSTA er kontraindiceret (se pkt.
The combination of avanafil and REZOLSTA is contraindicated (see section 4.3).
REZOLSTA og dolutegravir kan anvendes uden dosisjustering.
REZOLSTA and dolutegravir can be used without dose adjustments.
Baseret på teoretiske overvejelser kan REZOLSTA muligvis ændre plasmakoncentrationen af warfarin.
Based on theoretical considerations REZOLSTA may alter warfarin plasma concentrations.
CD4+ celletal gennemsnitlig ændring fra baseline
CD4+ cell count mean change from baseline
Lever og galdeveje almindelig forhøjede leverenzymer ikke almindelig hepatitis*, cytolytisk hepatitis*
Uncommon hepatitis*, cytolytic hepatitis*
- clonazepam (til at hindre krampeanfald) - østrogenholdig prævention og hormonerstatningsbehandling.
- Clonazepam (to prevent seizures).
Behandling med 800/150 mg darunavir/cobicistat under graviditet fører til lav eksponering for darunavir (se pkt.
Treatment with darunavir/cobicistat 800/150 mg during pregnancy results in low darunavir exposure (see section 5.2), which may be associated with an increased risk of treatment failure and an increased risk of HIV transmission to the child.
(CYP3A-hæmning og/eller P-gp-hæmning)
(CYP3A inhibition and/or P-gp inhibition)
Hiv-1 RNA < 50 kopier/ml Hiv-1 RNA gennemsnitlig ændring fra baseline (log10kopier/ml)
HIV-1 RNA < 50 copies/mL mean HIV-1 RNA log change from baseline (log10 copies/mL) CD4+ cell count mean change from baseline
Almene symptomer og reaktioner på administrationsstedet almindelig
General disorders and administration site conditions Common fatigue, asthenia
Baseret på teoretiske overvejelser forventes REZOLSTA at øge plasmakoncentrationen af digoxin.
Based on theoretical considerations REZOLSTA is expected to increase digoxin plasma concentrations.
Resultater darunavir/ritonavir 800/100 mg en gang dagligt + OBR N=294
Outcomes darunvir/ritonavir 800/100 mg once daily + OBR N = 294
Baseret på teoretiske overvejelser forventes REZOLSTA at øge plasmakoncentrationen af maraviroc.
Based on theoretical considerations REZOLSTA is expected to increase maraviroc plasma concentrations.
Udslæt
urticaria
Et biotilgængelighedsstudie viste, at eksponeringen for darunavir er sammenlignelig mellem REZOLSTA og darunavir/ritonavir 800/100 mg en gang dagligt ved steady state hos ikke-fastende raske forsøgspersoner.
Darunavir exposure was shown to be comparable in a bioavailability trial between REZOLSTA and darunavir/ritonavir 800/100 mg q.d.
Behandlingserfarne darunavir/ritonavir 800/100 mg en gang dagligt N=294
Treatment-experienced darunavir/ritonavir 800/100 mg once daily N = 294
Det frarådes at co-administrere REZOLSTA med bosentan.
Co-administration of REZOLSTA and bosentan is not recommended.
voriconazol må kun tages, når en læge har bedømt brugen af det. - rifabutin (mod bakterieinfektioner).
Voriconazole should only be taken after medical evaluation.
4.5): - carbamazepin, phenobarbital, phenytoin - rifampicin - lopinavir/ritonavir - perikon (Hypericum perforatum).
Co-administration with the following medicinal products due to the potential for loss of therapeutic effect (see section 4.5): - carbamazepine, phenobarbital, phenytoin - rifampicin - lopinavir/ritonavir - St John's wort, (Hypericum perforatum).
Baseret på teoretiske overvejelser kan REZOLSTA muligvis ændre plasmakoncentrationen af norethisteron.
Based on theoretical considerations REZOLSTA may alter norethindrone plasma concentrations.
Amiodaron, bepridil, dronedaron, ivabradin, kinidin, ranolazin til behandling af visse hjertelidelser som f.eks. unormal hjerterytme Carbamazepin, phenobarbital og phenytoin til forebyggelse af krampeanfald Astemizol eller terfenadin til behandling af symptomer på allergi
Carbamazepine, phenobarbital and phenytoin to prevent seizures Astemizole or terfenadine to treat allergy symptoms
Alle patienter darunavir/cobicistat 800/150 mg en gang dagligt + OBR N=313
All subjects darunavir/cobicistat 800/150 mg once daily + OBR N = 313
(CYP3A- og/eller P-glykoproteinhæmning)
(CYP3A and/or P-glycoprotein inhibition)
- amitriptylin, desipramin, imipramin, nortriptylin, paroxetin, sertralin, trazodon (til behandling af depression og angst).
- Rifabutin (against bacterial infections) - Tadalafil, sildenafil, vardenafil (for erectile dysfunction or high blood pressure in the pulmonary circulation) - Amitriptyline, desipramine, imipramine, nortriptyline, paroxetine, sertraline, trazodone (to treat depression and anxiety) - Maraviroc (to treat HIV infection) - Colchicine (to treat gout or familial Mediterranean fever).
Behandlingsnaive darunavir/cobicistat 800/150 mg en gang dagligt + OBR N=295
Treatment-naïve darunavir/cobicistat 800/150 mg once daily + OBR N = 295
Behandlingsnaive darunavir/cobicistat 800/150 mg en gang dagligt N=295
Treatment-naïve darunavir/cobicistat 800/150 mg once daily N = 295
Baseret på teoretiske overvejelser forventes REZOLSTA at øge plasmakoncentrationen af salmeterol.
Based on theoretical considerations REZOLSTA is expected to increase salmeterol plasma concentrations.
Ved symptomer på alvorlige hudreaktioner skal REZOLSTA straks seponeres.
REZOLSTA should be discontinued immediately if signs or symptoms of severe skin reactions develop.
Baseret på teoretiske overvejelser forventes REZOLSTA at øge plasmakoncentrationen af colchicin.
Based on theoretical considerations REZOLSTA is expected to increase colchicine plasma concentrations.
Kontakt lægen, hvis du får udslæt.
Please contact your doctor whenever you develop a rash.
Baseret på teoretiske overvejelser forventes disse antimykobakterielle midler at nedsætte plasmakoncentrationen af darunavir og/eller cobicistat.
Based on theoretical considerations these antimycobacterials are expected to decrease darunavir and/or cobicistat plasma concentrations.
Baseret på teoretiske overvejelser forventes REZOLSTA at øge plasmakoncentrationen af tenofovir.
Based on theoretical considerations REZOLSTA is expected to increase tenofovir plasma concentrations.
Baseret på teoretiske overvejelser forventes REZOLSTA at øge plasmakoncentrationen af disse PDE-5-hæmmere.
Based on theoretical considerations REZOLSTA is expected to increase these PDE-5 inhibitor plasma concentrations.
Behandlingserfarne darunavir/cobicistat 800/150 mg en gang dagligt N=18
Treatment-experienced darunavir/cobicistat 800/150 mg once daily N = 18
Baseret på teoretiske overvejelser forventes REZOLSTA at øge plasmakoncentrationen af disse immunsuppressiva.
Based on theoretical considerations REZOLSTA is expected to increase these immunosuppressant plasma concentrations.
Det skal du vide, før du begynder at tage REZOLSTA Sådan skal du tage REZOLSTA Bivirkninger
What REZOLSTA is and what it is used for What you need to know before you take REZOLSTA How to take REZOLSTA
Den rapporterede tid til udbrud er variabel og kan være mange måneder efter behandlingsstart (se pkt.
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Baseret på teoretiske overvejelser forventes REZOLSTA at øge plasmakoncentrationen af alfentanil.
Based on theoretical considerations REZOLSTA is expected to increase alfentanil plasma concentrations.
Behandlingsnaive darunavir/ritonavir 800/100 mg en gang dagligt N=343
Treatment-naïve darunavir/ritonavir 800/100 mg once daily N = 343
Baseret på teoretiske overvejelser forventes REZOLSTA at øge plasmakoncentrationen af alfuzosin.
Based on theoretical considerations REZOLSTA is expected to increase alfuzosin plasma concentrations.
Baseret på teoretiske overvejelser forventes rifampicin at nedsætte plasmakoncentrationen af darunavir og/eller cobicistat.
Based on theoretical considerations rifampin is expected to decrease darunavir and/or cobicistat plasma concentrations.
Behandlingserfarne darunavir/cobicistat 800/150 mg en gang dagligt + OBR N=18
Treatment-experienced darunavir/cobicistat 800/150 mg once daily + OBR N = 18
Baseret på teoretiske overvejelser forventes REZOLSTA at øge plasmakoncentrationen af metformin.
Based on theoretical considerations REZOLSTA is expected to increase metformin plasma concentrations.
Resultater darunavir/ ritonavir 800/100 mg en gang dagligt N=343
Outcomes darunavir/ ritonavir 800/100 mg once daily N = 343
Baseret på teoretiske overvejelser forventes REZOLSTA at øge plasmakoncentrationen af disse antidepressiva.
Based on theoretical considerations REZOLSTA is expected to increase these anti-depressant plasma concentrations.
Der henvises til produktresuméet for maraviroc for yderligere oplysninger.
For further details, consult the maraviroc Summary of Product Characteristics.
Jernoxid, sort
Iron oxide black